Shanghai Institute of Materia Medica Chinese Academy of Sciences:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Shanghai Institute of Materia Medica Chinese Academy of Sciences - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9316
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shanghai Institute of Materia Medica Chinese Academy of Sciences (SIMM) is an educational research institute that provides research and development of traditional Chinese medicine. The institute offers solutions in the areas of drug discovery and drug development. It also offers studies of structure-activity relationships of bioactive substances, new chemical entities, pre-clinical evaluation and pharmaceutical development. SIMM develops drugs such as artemether, dimercaptosuccinic acid, and huperzine a, depsides salts, antofloxacin hydrochloride, and others. The institute carries out research in the areas of drug screening, pharmacology, medicinal chemistry, products chemistry, combinatorial chemistry, toxicology, pharmacokinetics and computer-aided drug design, among others. SIMM is headquartered in Pudong, China.

Shanghai Institute of Materia Medica Chinese Academy of Sciences – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Shandong Luoxin Pharma Enters into Agreement with Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Fudan University 10
TechnoPhage Enters into Co-Development Agreement with Shanghai Institute of Materia Medica 11
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 12
Licensing Agreements 13
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 13
Asset Transactions 14
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 14
Shanghai Institute of Materia Medica Chinese Academy of Sciences – Key Competitors 16
Shanghai Institute of Materia Medica Chinese Academy of Sciences – Key Employees 17
Shanghai Institute of Materia Medica Chinese Academy of Sciences – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Government and Public Interest 19
Jun 22, 2018: Scientists Make a Major Breakthrough in Signal Transduction of GPCR 19
Product News 20
Aug 30, 2018: Biomimetic strategy realizes imaging-guided treatment of Breast Cancer Metastasis 20
Jan 03, 2018: Glucagon Receptor Structure Offers New Opportunities for Type 2 Diabetes Drug Discovery 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Key Facts 2
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Deals By Therapy Area, 2012 to YTD 2018 8
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Shandong Luoxin Pharma Enters into Agreement with Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Fudan University 10
TechnoPhage Enters into Co-Development Agreement with Shanghai Institute of Materia Medica 11
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 12
Servier Enters Into Licensing Agreement With Shanghai Institute Of Materia Medica 13
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 14
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Key Competitors 16
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Key Employees 17

List of Figures
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Shanghai Institute of Materia Medica Chinese Academy of Sciences, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Shanghai Institute of Materia Medica Chinese Academy of Sciences:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HeartWare International Inc:企業の戦略的SWOT分析
    HeartWare International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • W. L. Gore & Associates Inc-医療機器分野:企業M&A・提携分析
    Summary W. L. Gore & Associates Inc (Gore) is a manufacturer and distributor of fluoropolymer products. Its product portfolio includes consumer products, cables, electronic components, fabrics, fibers, medical, pharmaceutical, sealing and vents. The company has developed numerous products for medica …
  • Genalyte Inc:医療機器:M&Aディール及び事業提携情報
    Summary Genalyte Inc (Genalyte) is a lab testing service provider. The company’s services include data analysis, phlebotomist for blood draw, integration with existing emr, phlebotomist for blood draw, applications for test order and results review and clinical lab scientist. It provides instruments …
  • Centre for Drug Design and Discovery:製薬・医療:M&Aディール及び事業提携情報
    Summary Centre for Drug Design and Discovery (CD3) is a biomedical research institution that discovers new small molecule drugs. The institution operates as an investment fund and technology transfer platform to promote the discovery and development of medicines for all kinds of diseases. It provide …
  • Aslan Pharmaceuticals Pte Ltd (6497):製薬・医療:M&Aディール及び事業提携情報
    Summary Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhib …
  • Futuren (FTRN):電力:M&Aディール及び事業提携情報
    Summary Futuren, previously Theolia SA, is a wind energy producer that prospects, develops, constructs, installs and operates wind power projects. It specializes in designing and building onshore wind plants. Futuren conducts these operations for its own account as well as for third parties. The com …
  • Hanwha Q CELLS Co Ltd (HQCL):企業の財務・戦略的SWOT分析
    Hanwha Q CELLS Co Ltd (HQCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Oci Nv:企業の戦略・SWOT・財務分析
    Oci Nv - Strategy, SWOT and Corporate Finance Report Summary Oci Nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Safeguard Scientifics Inc (SFE):企業の財務・戦略的SWOT分析
    Summary Safeguard Scientifics Inc (Safeguard Scientifics), formerly Lancaster Corp, is a provider of finance, healthcare and digital media solutions. The company offers business intelligence and analytics for institutional/capital markets, insurance technology, regulatory and compliance technology a …
  • Evolution Petroleum Corp (EPM):石油・ガス:M&Aディール及び事業提携情報
    Summary Evolution Petroleum Corp (EPC), a subsidiary of Esrey Resources Ltd, is an oil and gas company that acquires and explores crude oil and natural gas properties. The company explores for oil, liquefied gas, natural gas, and gas reserves in Delhi field CO2-EOR project. It offers GARP or gas ass …
  • John Menzies plc:戦略・SWOT・企業財務分析
    John Menzies plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • SugarBud Craft Growers Corp (RRL):企業の財務・戦略的SWOT分析
    Summary SugarBud Craft Growers Corp, (SugarBud) formerly New Range Resources Ltd is an oil and gas company that offers oil and gas exploration and development services. The company acquires, explores, operates, manages, produces, and develops crude oil and natural gas in Alberta and Saskatchewan. It …
  • Indiana University Health Inc:企業の戦略的SWOT分析
    Indiana University Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • The Capital Group Companies, Inc.:企業の戦略・SWOT・財務分析
    The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • STRATEC Biomedical AG (SBS):企業の財務・戦略的SWOT分析
    Summary STRATEC Biomedical AG (STRATEC), formerly Stratec Biomedical Systems AG is a medical equipment provider that develops and manufactures automated systems for clinical diagnostics. The company provides instrumentation, data management, molecular solutions, and others. It offers data management …
  • Symantec Corporation:企業の戦略・SWOT・財務分析
    Symantec Corporation - Strategy, SWOT and Corporate Finance Report Summary Symantec Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Po Valley Energy Ltd (PVE):企業の財務・戦略的SWOT分析
    Summary Po Valley Energy Ltd (Po Valley Energy) is an oil and gas company that offers exploration and development of hydrocarbon assets. The company's projects include Sillaro, Castello or Bezzecca, Sant'Alberto, Teodorico and Selva. Its Sillaro field is located in the province of Bologna with seven …
  • Stellar Biotechnologies Inc (SBOT):製薬・医療:M&Aディール及び事業提携情報
    Summary Stellar Biotechnologies Inc (Stellar Bio), formerly CAG Capital Inc is a provider of keyhole limpet hemocyanin proteins. The company offers potent immune-stimulating molecule used as an active pharmaceutical ingredient known as active immunotherapies or therapeutic vaccines and as an injecta …
  • Hammerson plc:企業のM&A・事業提携・投資動向
    Hammerson plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hammerson plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Currence Holding B.V.:企業の戦略・SWOT・財務情報
    Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆